Sean Saint

They wrote that big upfront check for somebody who was only on their plan for a year or less than a year.

And then they go to another plan.

Now that other plan might try and get the idea that they already have a pump and not buy them another one.

That's a bunch of, you know, of work in effect, or they can just continue paying for the pay as you go model and not worry about it.

It's just easier for everybody.

Yeah, from, and I believe we said over 25% are, we believe are type two patients.

From our perspective, they're really not because when considering that we don't have an indication for type two diabetes, we don't sell to type two diabetes in any way.

We don't talk about type two.

We don't push it in that regard.

But what we do do is show up in the health care provider's office and explain what the islet is and show them the clinical data and show them the product.

And it's always been this way.

A health care provider can choose to write a product for any person that they want.

And it turns out that that's how ours gets used.

This is really not that different from some of the other pumps.

I think we broadly have enough information now to say that AID generally seems to work in type two as well as it does in type one.

Although, again, there have been studies on some of the products and not others and not ours, in fact.

So still, you know, building that from an indication standpoint.

Type 2 diabetes is interesting, though, because so many more of them are being managed by primary care physicians.

Something like 85% are being seen by primary care, whereas on the type 1 side, it's more like, you know, 50 to 60% are being seen by primary care physicians.

So we really need to make sure that we make a product that's applicable for a particular user, but also for a particular health care provider on the type 1 or the type 2 side.